ArticleClinical pharmacology in drug development2021

Phase 1 Concentration-QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT-232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia.

Adekemi Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.